Xeris Biopharma Holdings, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a XERS research report →
Companywww.xerispharma.com
Xeris Biopharma Holdings, Inc. , a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.
- CEO
- John Shannon
- IPO
- 2018
- Employees
- 394
- HQ
- Chicago, IL, US
Price Chart
Valuation
- Market Cap
- $1.08B
- P/E
- 88.47
- P/S
- 3.42
- P/B
- 81.65
- EV/EBITDA
- 22.28
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 81.59%
- Op Margin
- 11.40%
- Net Margin
- 3.81%
- ROE
- 735.00%
- ROIC
- 12.84%
Growth & Income
- Revenue
- $291.85M · 43.72%
- Net Income
- $554.00K · 101.01%
- EPS
- $0.00 · 100.95%
- Op Income
- $24.90M
- FCF YoY
- 173.79%
Performance & Tape
- 52W High
- $10.08
- 52W Low
- $4.30
- 50D MA
- $5.95
- 200D MA
- $7.13
- Beta
- 0.92
- Avg Volume
- 1.86M
Get TickerSpark's AI analysis on XERS
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 1, 26 | Hecht Beth | sell | 16,667 |
| Apr 1, 26 | Hecht Beth | sell | 16,667 |
| Mar 30, 26 | Brady James Aloysius | sell | 10,834 |
| Mar 12, 26 | McCulloch Kevin | other | 4 |
| Mar 12, 26 | McCulloch Kevin | other | 48,894 |
| Mar 12, 26 | McCulloch Kevin | other | 4 |
| Mar 12, 26 | McCulloch Kevin | other | 48,894 |
| Mar 5, 26 | Pieper Steven | other | 14,036 |
| Mar 5, 26 | Pieper Steven | other | 27,891 |
| Mar 5, 26 | Pieper Steven | other | 27,891 |
Our XERS Coverage
We haven't published any research on XERS yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate XERS Report →